Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants - Wikidata - wikimedia - TriplyDB

Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants

Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants

http://www.wikidata.org/entity/Q34639828

about

Diarrheagenic Escherichia coli Emerging Applications of Bacterial Spores in Nanobiotechnology Adjuvants: Classification, Modus Operandi, and Licensing Plague Vaccine Development: Current Research and Future Trends Crystal structure of heat-labile enterotoxin from Escherichia coli with increased thermostability introduced by an engineered disulfide bond in the A subunit Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli.Adjuvant activity of a nontoxic mutant of Escherichia coli heat-labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live Salmonella enterica serovar Typhimurium vaccine strain Mutational analysis of the Helicobacter pylori vacuolating toxin amino terminus: identification of amino acids essential for cellular vacuolation Mucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside-binding activities.Exploring novel vaccines against Helicobacter pylori: protective and therapeutic immunization.Contributions of edema factor and protective antigen to the induction of protective immunity by Bacillus anthracis edema toxin as an intranasal adjuvant A recombinant live attenuated strain of Vibrio cholerae induces immunity against tetanus toxin and Bordetella pertussis tracheal colonization factor.Inhibition of class II major histocompatibility complex antigen processing by Escherichia coli heat-labile enterotoxin requires an enzymatically active A subunit Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins.Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge.Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant.Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.The immune responses to bacterial antigens encountered in vivo at mucosal surfaces.Effects of site-directed mutagenesis of Escherichia coli heat-labile enterotoxin on ADP-ribosyltransferase activity and interaction with ADP-ribosylation factors.Zonula occludens toxin is a powerful mucosal adjuvant for intranasally delivered antigens.Prior immunity to homologous and heterologous Salmonella serotypes suppresses local and systemic anti-fragment C antibody responses and protection from tetanus toxin in mice immunized with Salmonella strains expressing fragment C Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections.Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile.Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections.Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.Coimmunization with complementary glucosyltransferase peptides results in enhanced immunogenicity and protection against dental caries.Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii.Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.Vaccine adjuvants: current state and future trends.T-cell-mediated mucosal immunity in the absence of antibody: lessons from Helicobacter pylori infection.A revisit of mucosal IgA immunity and oral tolerance.Vaccination against Helicobacter pylori--an old companion of man.Nasal delivery of antigen with the B subunit of Escherichia coli heat-labile enterotoxin augments antigen-specific T-cell clonal expansion and differentiation.Bacterial spores as vaccine vehicles.Reduction of the ganglioside binding activity of the tetanus toxin HC fragment destroys immunogenicity: implications for development of novel tetanus vaccines.Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.Evaluation of the LTK63 adjuvant effect on cellular immune responses to measles virus nucleoprotein.Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines.

P2860

Q24533466-CB504BDA-23FF-4E4F-AE91-1519AC567CAB Q24806421-5FBA9FFE-3098-46CD-B8FB-B1EA5D51F491 Q26747586-F9D6202A-3D45-4FC1-83AB-A2B673E5A4E9 Q28066875-77E4A904-8CD6-4720-AD29-9D043DDD48A7 Q30429147-41617E91-F350-495B-AA84-10FE92C2C40B Q33597022-29F62BEA-5650-4403-B701-68DAE56C7C54 Q33599389-527B1F2C-015F-470A-9B18-63D69FEBBA32 Q33599414-BFE06A60-ACFD-4DB8-95BB-5DAA887B49AE Q33715999-D1F5C6DA-2B20-420B-A824-413E62A049ED Q33727845-FF089C0D-A735-4391-B14B-C0E5ED75812B Q33741147-B423EC3A-350E-4B01-897F-2EB4159D3B47 Q33752525-5A8C0129-59CB-4968-82B5-F9D5B242F796 Q33757092-4483CEA1-8D4B-4026-ADF8-D9B5863A47B3 Q33768109-8C37379C-1D8C-491E-80D0-DBBDED3CE645 Q33783470-C651C338-232B-4344-9B1F-FB255D05CE56 Q33837275-3546F8D0-F541-431E-8BBE-B9519F503C5E Q33846577-F9695CC8-3D35-4E7B-9EF5-E622489B537B Q33866797-B902724D-B9DE-4E39-BD50-4B5323846DFE Q33955531-BB553325-C517-4B97-B870-47D183CBFCAD Q34000007-359F03A9-8BDE-4196-B928-4EC390F96049 Q34000623-A1C7FF05-D843-43A7-BD80-07F130173A12 Q34001326-96EA9311-C9ED-4F02-95C3-4455F07372C0 Q34001509-FB86F003-A3F9-4B1A-9525-331C6D82B9B0 Q34001658-A0FB41E5-F78B-4CFF-9D06-852E8B563691 Q34002040-6F504966-768F-4D3F-8CD9-A446E3F455F3 Q34002470-BD7CA438-CEA4-4A6C-985F-FF716884968F Q34002672-A40085B5-943C-4898-9EA9-9F22990853F4 Q34004283-0FDC1A42-375A-4145-8B67-6DD4298B1AC8 Q34006385-B9E5ED3B-A85C-484C-AB6A-0086AAEB3D72 Q34184890-58FC2B5D-7730-4493-BCBC-694D1D652A93 Q34358206-C9B154C8-908E-4E8B-BE73-96235B00A884 Q34380115-45F2AE7A-BB9B-4037-824A-17EBB5BA5318 Q34419871-BF019C3E-18D9-4874-9F8F-CB1823392599 Q34452623-E91DF38B-B35D-4214-AB80-131B323B20B0 Q34761512-C0EEEF71-D361-4DDC-BC22-75DEAC2AEF83 Q34935167-E2208DB6-7F20-4C52-AC4E-6B5EBDCEC07C Q34975864-ADF73281-F908-4E96-A9C4-14E309FAE37F Q35066293-64B64047-A272-48F9-A3B2-38AFDD86723C Q35171910-CECE36BD-F1B4-4089-B112-47E75A6EB243 Q35192203-F2BC884E-C44F-41E8-895F-EA143F344FAA

P2860

Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants

http://www.wikidata.org/entity/Q34639828

description

1995 nî lūn-bûn

@nan

1995 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

1995 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

1995年の論文

@ja

1995年論文

@yue

1995年論文

@zh-hant

1995年論文

@zh-hk

1995年論文

@zh-mo

1995年論文

@zh-tw

1995年论文

@wuu

name

Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants

@ast

Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants

@en

Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants

@nl

type

label

Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants

@ast

Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants

@en

Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants

@nl

prefLabel

Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants

@ast

Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants

@en

Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants

@nl

P1433

Q34639828-D886AD11-0B12-4E80-82D5-4179CD27707A

P1476

Q34639828-BABCE303-33FF-4531-B14E-79B11C224C79

P2093

Q34639828-8FBC8957-5832-4B86-A35E-8AA6E9619483

Q34639828-96D1AAEC-CDE7-4B77-B63B-8342B8E1B684

Q34639828-AEF9ED71-AAF7-4E4D-B768-90878D3C0FE2

Q34639828-B858F2E8-A9BB-4C21-9A59-7E8241A8A877

Q34639828-CB94FBCB-ABED-4F6C-BA4A-97B9971B93F2

Q34639828-DAC6D9A9-CA30-4001-AB35-433016D3AE01

Q34639828-FA637C53-1EBB-43BA-9195-FA805CAB45AA

P2860

Q34639828-12266662-51F8-4154-BEBE-DF4F3A5BD043

Q34639828-1DEAF4BD-8641-40E1-A414-0372DD0CDB76

Q34639828-2319495B-78BF-4946-AD87-574CEB1D7823

Q34639828-26362D1C-70CF-4E16-93C4-AFBE31D9EF0E

Q34639828-2B7D5559-5A0A-496F-A21D-78F8300931E6

Q34639828-2F5D6307-41EC-4644-A8C0-3DB1228EAF1D

Q34639828-3835A70C-7819-46BC-89FA-94E412C27BD7

Q34639828-CBAC013F-39E9-4D01-AAE9-8CBDAB3AFF01

Q34639828-CDBFDCA0-363C-45AE-9D6E-968F903B380D

Q34639828-D3795368-9DEE-40E7-B179-5F9496ED402B

P304

Q34639828-4981CB27-2E4B-4F4A-9F69-48FDB11C8065

P31

Q34639828-34EF7CC1-C5B7-4BC1-9C67-1A9BFBA24983

P356

Q34639828-A41A2F87-0B03-426B-95E8-DFEBD620D7A3

P407

Q34639828-1FFEE316-CAD7-422F-946E-0E8328B5A667

P433

Q34639828-51024560-5DE4-45BD-AA79-2D79D3DA404D

P478

Q34639828-34ACC3B9-6CF1-4442-807F-EDD84B249CFD

P50

Q34639828-8925F0A5-ED1D-4EC8-BD35-4EC0D99E4660

P577

Q34639828-EDE5DC25-03F4-4608-87DB-29C8A1518D30

P5875

Q34639828-DD0CE88D-BB35-48A9-B3C8-D24C95B1F398

P698

Q34639828-05026496-9294-4DB1-AE9E-03B230041917

P921

Q34639828-69E2E056-D62F-40D5-BB24-BCAE2ECD5799

P932

Q34639828-8AE33F27-759A-4EF7-BC27-15284D6B9D59

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Mutants of Escherichia coli he ...... as nontoxic, mucosal adjuvants

@en

P2093

Cropley I

http://www.w3.org/2001/XMLSchema#string

Domenghini M

http://www.w3.org/2001/XMLSchema#string

Douce G

http://www.w3.org/2001/XMLSchema#string

Dougan G

http://www.w3.org/2001/XMLSchema#string

Pizza M

http://www.w3.org/2001/XMLSchema#string

Roberts M

http://www.w3.org/2001/XMLSchema#string

Turcotte C

http://www.w3.org/2001/XMLSchema#string

P2860

Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant.

Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues.

Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin

The mucosal immune system: from fundamental concepts to vaccine development.

Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin.

Detection of heat-labile Escherichia coli enterotoxin with the use of adrenal cells in tissue culture.

Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli.

Current progress in the development of the B subunits of cholera toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes.

1993 Colworth Prize Lecture. The molecular basis for the virulence of bacterial pathogens: implications for oral vaccine development.

Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems.

P304

1644-1648

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.92.5.1644

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P50

P577

1995-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

15321260

http://www.w3.org/2001/XMLSchema#string

P698

7878032

http://www.w3.org/2001/XMLSchema#string

P921

Escherichia coli

P932

42576

http://www.w3.org/2001/XMLSchema#string